open access

Vol 85, No 3 (2017)
REVIEWS
Published online: 2017-06-30
Submitted: 2017-01-02
Accepted: 2017-04-12
Get Citation

Respiratory system involvement in inflammatory bowel diseases

Aneta Kacprzak, Monika Szturmowicz, Jan Kus
DOI: 10.5603/ARM.2017.0028
·
Adv Respir Med 2017;85(3):161-168.

open access

Vol 85, No 3 (2017)
REVIEWS
Published online: 2017-06-30
Submitted: 2017-01-02
Accepted: 2017-04-12

Abstract

Inflammatory bowel diseases are systemic disorders that can manifest in any location. The problem of respiratory system involvement is very important form clinical point of view. In the article we try to systematize the current knowledge on this topic.

Abstract

Inflammatory bowel diseases are systemic disorders that can manifest in any location. The problem of respiratory system involvement is very important form clinical point of view. In the article we try to systematize the current knowledge on this topic.

Get Citation

Keywords

inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, lung diseases, airways diseases

About this article
Title

Respiratory system involvement in inflammatory bowel diseases

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 3 (2017)

Pages

161-168

Published online

2017-06-30

DOI

10.5603/ARM.2017.0028

Bibliographic record

Adv Respir Med 2017;85(3):161-168.

Keywords

inflammatory bowel diseases
Crohn’s disease
ulcerative colitis
lung diseases
airways diseases

Authors

Aneta Kacprzak
Monika Szturmowicz
Jan Kus

References (100)
  1. Burisch J, Jess T, Martinato M, et al. ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013; 7(4): 322–337.
  2. Bamias G, Nyce MR, De La Rue SA, et al. American College of Physicians, American Physiological Society. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005; 143(12): 895–904.
  3. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003; 9(10): 2300–2307.
  4. Edwards FC, Truelove SC. THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. Gut. 1963; 4: 299–315.
  5. Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014; 20(46): 17463–17467.
  6. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001; 96(4): 1116–1122.
  7. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005; 129(3): 827–836.
  8. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994; 107(1): 103–108.
  9. Ornitz DM, Yin Y. Signaling networks regulating development of the lower respiratory tract. Cold Spring Harb Perspect Biol. 2012; 4(5).
  10. Mestecky J. The common mucosal immune system and current strategies for introduction of immune responses in external secretions. J Clin Immunol . 1987; 74: 265–267.
  11. Rogers BH, Clark LM, Kirsner JB. The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis. 1971; 24(12): 743–773.
  12. Casey MB, Tazelaar HD, Myers JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol. 2003; 27(2): 213–219.
  13. Isenberg JI, Goldstein H, Korn AR, et al. Pulmonary vasculitis--an uncommon complication of ulcerative colitis. Report of a case. N Engl J Med. 1968; 279(25): 1376–1377.
  14. Kraft SC, Earle RH, Roesler M, et al. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med. 1976; 136(4): 454–459.
  15. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9(2): 104–115.
  16. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007; 131(2): 524–532.
  17. Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol. 2014; 20(37): 13501–13511.
  18. Papanikolaou I, Kagouridis K, Papiris SA. Patterns of airway involvement in inflammatory bowel diseases. World J Gastrointest Pathophysiol. 2014; 5(4): 560–569.
  19. Raj AA, Birring SS, Green R, et al. Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med. 2008; 102(5): 780–785.
  20. Brassard P, Vutcovici M, Ernst P, et al. Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. Eur Respir J. 2015; 45(4): 962–968.
  21. Hemminki K, Li X, Sundquist J, et al. Subsequent autoimmune or related disease in asthma patients: clustering of diseases or medical care? Ann Epidemiol. 2010; 20(3): 217–222.
  22. Birring SS, Morgan AJ, Prudon B, et al. Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. Thorax. 2003; 58(6): 533–536.
  23. Douglas JG, McDonald CF, Leslie MJ, et al. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respir Med. 1989; 83(5): 389–394.
  24. Songür N, Songür Y, Tüzün M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003; 37(4): 292–298.
  25. Mohamed-Hussein AAR, Mohamed NAS, Ibrahim MEAR. Changes in pulmonary function in patients with ulcerative colitis. Respir Med. 2007; 101(5): 977–982.
  26. Yilmaz A, Yilmaz Demirci N, Hoşgün D, et al. Pulmonary involvement in inflammatory bowel disease. World J Gastroenterol. 2010; 16(39): 4952–4957.
  27. Desai D, Patil S, Udwadia Z, et al. Pulmonary manifestations in inflammatory bowel disease: a prospective study. Indian J Gastroenterol. 2011; 30(5): 225–228.
  28. Ateş F, Karincaoğlu M, Hacievlıyagıl SS, et al. Alterations in the pulmonary function tests of inflammatory bowel diseases. Turk J Gastroenterol. 2011; 22(3): 293–299.
  29. Louis E, Louis R, Drion V, et al. Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease. Allergy. 1995; 50(9): 729–733.
  30. Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med. 2000; 161(3 Pt 1): 1051–1054.
  31. Ceyhan BB, Karakurt S, Cevik H, et al. Bronchial hyperreactivity and allergic status in inflammatory bowel disease. Respiration. 2003; 70(1): 60–66.
  32. Karadag F, Ozhan MH, Akçiçek E, et al. Is it possible to detect ulcerative colitis-related respiratory syndrome early? Respirology. 2001; 6(4): 341–346.
  33. Fireman E, Masarwy F, Groisman G, et al. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine? Respir Med. 2009; 103(7): 1025–1032.
  34. Louis E, Louis R, Shute J, et al. Bronchial eosinophilic infiltration in Crohn's disease in the absence of pulmonary disease. Clin Exp Allergy. 1999; 29(5): 660–666.
  35. Fireman Z, Osipov A, Kivity S, et al. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol. 2000; 95(3): 730–734.
  36. Bonniere P, Wallaert B, Cortot A, et al. Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut. 1986; 27(8): 919–925.
  37. Koek GH, Verleden GM, Evenepoel P, et al. Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement? Respir Med. 2002; 96(7): 530–535.
  38. Ozyilmaz E, Yildirim B, Erbas G, et al. Value of fractional exhaled nitric oxide (FE NO) for the diagnosis of pulmonary involvement due to inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(4): 670–676.
  39. Malerba M, Ragnoli B, Buffoli L, et al. Exhaled nitric oxide as a marker of lung involvement in Crohn's disease. Int J Immunopathol Pharmacol. 2011; 24(4): 1119–1124.
  40. Gursoy S, Guven K, Kula M, et al. Subclinical alveolar involvement in ulcerative colitis. Inflamm Bowel Dis. 2005; 11(4): 372–375.
  41. Adenis A, Colombel JF, Lecouffe P, et al. Increased pulmonary and intestinal permeability in Crohn's disease. Gut. 1992; 33(5): 678–682.
  42. Robertson DA, Taylor N, Sidhu H, et al. Pulmonary permeability in coeliac disease and inflammatory bowel disease. Digestion. 1989; 42(2): 98–103.
  43. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993; 72(3): 151–183.
  44. Higenbottam T, Cochrane GM, Clark TJ, et al. Bronchial disease in ulcerative colitis. Thorax. 1980; 35(8): 581–585.
  45. Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest. 1998; 113(6): 1723–1726.
  46. Hamada S, Ito Y, Imai S, et al. Effect of inhaled corticosteroid therapy on CT scan-estimated airway dimensions in a patient with chronic bronchitis related to ulcerative colitis. Chest. 2011; 139(4): 930–932.
  47. Kuźniar T, Sleiman C, Brugière O, et al. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J. 2000; 15(1): 209–212.
  48. Plataki M, Tzortzaki E, Lambiri I, et al. Severe airway stenosis associated with Crohn's disease: case report. BMC Pulm Med. 2006; 6: 7.
  49. Lu DG, Ji XQ, Zhao Qi, et al. Tracheobronchial nodules and pulmonary infiltrates in a patient with Crohn's disease. World J Gastroenterol. 2012; 18(39): 5653–5657.
  50. Tzanakis N, Samiou M, Bouros D, et al. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med. 1998; 157(2): 382–386.
  51. Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000; 15(1): 41–48.
  52. Rajoriya N, Wotton CJ, Yeates DGR, et al. Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database. Postgrad Med J. 2009; 85(1003): 233–237.
  53. Studdy P, Bird R, James DG. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet. 1978; 2(8104-5): 1331–1334.
  54. Matsuda T, Suzuki J, Furuya K, et al. Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genotype. Am J Gastroenterol. 2001; 96(9): 2705–2710.
  55. Letizia C, D'Ambrosio C, Agostini D, et al. Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis. Ital J Gastroenterol. 1993; 25(1): 23–25.
  56. Beer TW, Edwards CW. Pulmonary nodules due to reactive systemic amyloidosis (AA) in Crohn's disease. Thorax. 1993; 48(12): 1287–1288.
  57. Alrashid AI, Brown RD, Mihalov ML, et al. Crohn's disease involving the lung: resolution with infliximab. Dig Dis Sci. 2001; 46(8): 1736–1739.
  58. Gill KRS, Mahadevan U. Infliximab for the treatment of metastatic hepatic and pulmonary Crohn's disease. Inflamm Bowel Dis. 2005; 11(2): 210–212.
  59. Nguyen T, Shepela C, Patnaik M, et al. Pulmonary nodules as an extra-intestinal manifestation of inflammatory bowel disease: a case series and review of the literature. Dig Dis Sci. 2009; 54(5): 1135–1140.
  60. Warwick G, Leecy T, Silverstone E, et al. Pulmonary necrobiotic nodules: a rare extraintestinal manifestation of Crohn's disease. Eur Respir Rev. 2009; 18(111): 47–50.
  61. Carrascosa MF, Salcines-Caviedes JR, Millán MV, et al. Pulmonary nodules as respiratory manifestation of inflammatory bowel disease: case report and review. Inflamm Bowel Dis. 2011; 17(8): E99–101.
  62. Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir J. 2002; 19(4): 756–764.
  63. Foster RA, Zander DS, Mergo PJ, et al. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003; 9(5): 308–315.
  64. Kacprzak A, Siemion-Szcześniak I, Szturmowicz M, et al. Pulmonary pathology in patients with ulcerative colitis treated with mesalazine--a challenging and complex diagnostic problem. Case series and literature review. Pneumonol Alergol Pol. 2014; 82(4): 368–376.
  65. Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007; 41(7): 682–688.
  66. Nagy F, Molnar T, Makula E, et al. A case of interstitial pneumonitis in a patient with ulcerative colitis treated with azathioprine. World J Gastroenterol. 2007; 13(2): 316–319.
  67. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000; 15(2): 373–381.
  68. Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J Crohns Colitis. 2010; 4(2): 211–214.
  69. Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002; 8(3): 186–191.
  70. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86(4): 242–251.
  71. Reid JD, Bressler B, English J. A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease. Can Respir J. 2011; 18(5): 262–264.
  72. Hamadeh M, Atkinson J, Smith L. Sulfasalazine-induced Pulmonary Disease. Chest. 1992; 101(4): 1033–1037.
  73. Sesin GP, Mucciardi N, Almeida S. Mesalamine-associated pleural effusion with pulmonary infiltration. Am J Health Syst Pharm. 1998; 55(21): 2304–2305.
  74. Trisolini R, Dore R, Biagi F, et al. Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence. Sarcoidosis Vasc Diffuse Lung Dis. 2000; 17(3): 288–291.
  75. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098–1104.
  76. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007; 52(6): 1481–1484.
  77. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126(1): 19–31.
  78. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008; 83(2): 181–194.
  79. Cohen RD, Bowie WR, Enns R, et al. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007; 62(11): 1013–1014.
  80. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134(4): 929–936.
  81. Ghahremani GG, Gore RM, Breuer RI, et al. Esophageal manifestations of Crohn's disease. Gastrointest Radiol. 1982; 7(3): 199–203.
  82. Cynn WS, Chon H, Gureghian PA, et al. Crohn's disease of the esophagus. Am J Roentgenol Radium Ther Nucl Med. 1975; 125(2): 359–364.
  83. Steel A, Dyer NH, Matthews HR. Cervical Crohn's disease with oesophago-pulmonary fistula. Postgrad Med J. 1988; 64(755): 706–709.
  84. Karmy-Jones R, Chagpar A, Vallieres E, et al. Colobronchial fistula due to Crohn's disease. Ann Thorac Surg. 1995; 60(2): 446–448.
  85. Mera A, Sugimoto M, Fukuda K, et al. Crohn's disease associated with colo-bronchial fistula. Intern Med. 1996; 35(12): 957–960.
  86. Domej W, Kullnig P, Petritsch W, et al. Colobronchial fistula: a rare complication of Crohn's colitis. Am Rev Respir Dis. 1990; 142(5): 1225–1227.
  87. Singh D, Cole JC, Cali RL, et al. Colobronchial fistula: an unusual complication of Crohn's disease. Am J Gastroenterol. 1994; 89(12): 2250–2252.
  88. Leichtling JJ, Garlock JH. Granulomatous colitis complicated by gastrocolic, duodenocolic, and colopulmonic fistulas. Gastroenterology. 1962; 43: 151–165.
  89. Gumbo T, Rice TW, Mawhorter S. Recurrent pneumonia from an ileobronchial fistula complicating Crohn's disease. J Clin Gastroenterol. 2001; 32(4): 365–367.
  90. Konstantinides SV, Torbicki A, Agnelli G, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033–69, 3069a.
  91. Yuhara H, Steinmaus C, Corley D, et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 37(10): 953–962.
  92. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010; 375(9715): 657–663.
  93. Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004; 99(1): 97–101.
  94. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010; 139(3): 779–87, 787.e1.
  95. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000; 35(6): 619–623.
  96. Balestra DJ, Balestra ST, Wasson JH. Ulcerative colitis and steroid-responsive, diffuse interstitial lung disease. A trial of N = 1. JAMA. 1988; 260(1): 62–64.
  97. Marten K, Fend F, Hautmann H, et al. Case report: Fatal acute exacerbation of usual interstitial pneumonia in ulcerative colitis. Br J Radiol. 2005; 78(932): 762–766.
  98. Marvisi M, Borrello PD, Brianti M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J. 2000; 16(5): 965–968.
  99. Pasquis P, Colin R, Denis P, et al. Transient pulmonary impairment during attacks of Crohn's disease. Respiration. 1981; 41(1): 56–59.
  100. Forrest JA, Shearman DJ. Pulmonary vasculitis and ulcerative colitis. Am J Dig Dis. 1975; 20(5): 482–486.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl